問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


E-DA Hospital (在職)

Division of Cardiovascular Diseases

更新時間：2023-09-19

曾維功
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

6Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

曾維功

List

23Cases

2009-07-01 - 2010-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2018-03-20 - 2024-03-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting9Sites

賴文德
Kaohsiung Municipal Gangshan Hospital

未分科

2026-03-01 - 2030-10-09

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting9Sites

2024-07-30 - 2028-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting8Sites

Recruiting2Sites

2025-05-01 - 2029-06-30

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2023-03-01 - 2027-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2023-04-13 - 2027-05-05

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2013-12-15 - 2016-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2014-12-01 - 2017-03-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy in South Korea and Taiwan

  • Condition/Disease

    High Cardiovascular Risk Patients With Hypercholesterolemia

  • Test Drug

    Alirocumab

Participate Sites
13Sites

Terminated13Sites

2015-08-01 - 2017-12-31

Phase III

A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of dupilumab in patients with persistent asthma

  • Condition/Disease

    persistent asthma

  • Test Drug

    dupilumab

Participate Sites
12Sites

Terminated10Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Cardiovascular Diseases

鍾啟禮
Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Cardiovascular Diseases

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB